✦ LIBER ✦

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

✍ Scribed by Sundar Jagannath; Bart Barlogie; James R. Berenson; David S. Siegel; David Irwin; Paul G. Richardson; Ruben Niesvizky; Raymond Alexanian; Steven A. Limentani; Melissa Alsina; Dixie-Lee Esseltine; Kenneth C. Anderson

Book ID: 108675971
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 85 KB
Volume: 143
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2008.07359.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and efficacy of bortezomib and me

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up

✍ James R. Berenson; Hank H. Yang; Robert A. Vescio; Youram Nassir; Russell Mapes; 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 164 KB

Long-term follow-up on overall survival

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

✍ Dimopoulos, M A; Chen, C; Spencer, A; Niesvizky, R; Attal, M; Stadtmauer, E A; P 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 164 KB

Error in a study of the outcome of mantl

Error in a study of the outcome of mantle cell lymphoma: Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur

✍ Christian H. Geisler; Arne Kolstad; Anna Laurell; Mats Jerkeman; Riikka Räty; Ni 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB